|
Gene: GSK3A |
Gene summary for GSK3A |
Gene summary. |
Gene information | Species | Human | Gene symbol | GSK3A | Gene ID | 2931 |
Gene name | glycogen synthase kinase 3 alpha | |
Gene Alias | GSK3A | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | A0A024R0L5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2931 | GSK3A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.84e-09 | 1.58e-01 | 0.0155 |
2931 | GSK3A | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.13e-13 | 3.51e-01 | -0.1808 |
2931 | GSK3A | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.26e-09 | 2.84e-01 | -0.0811 |
2931 | GSK3A | HTA11_78_2000001011 | Human | Colorectum | AD | 2.14e-07 | 1.99e-01 | -0.1088 |
2931 | GSK3A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.97e-12 | 2.30e-01 | -0.1954 |
2931 | GSK3A | HTA11_411_2000001011 | Human | Colorectum | SER | 4.21e-05 | 4.02e-01 | -0.2602 |
2931 | GSK3A | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.40e-07 | 4.17e-01 | -0.2196 |
2931 | GSK3A | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.43e-09 | 2.84e-01 | -0.1207 |
2931 | GSK3A | HTA11_83_2000001011 | Human | Colorectum | SER | 7.70e-11 | 2.99e-01 | -0.1526 |
2931 | GSK3A | HTA11_696_2000001011 | Human | Colorectum | AD | 1.54e-14 | 3.39e-01 | -0.1464 |
2931 | GSK3A | HTA11_866_2000001011 | Human | Colorectum | AD | 2.19e-05 | 2.24e-01 | -0.1001 |
2931 | GSK3A | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.21e-17 | 3.69e-01 | -0.059 |
2931 | GSK3A | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.05e-09 | 5.10e-01 | -0.1706 |
2931 | GSK3A | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.06e-04 | 2.01e-01 | -0.2061 |
2931 | GSK3A | HTA11_546_2000001011 | Human | Colorectum | AD | 1.33e-04 | 2.09e-01 | -0.0842 |
2931 | GSK3A | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.18e-02 | 2.95e-01 | -0.00410000000000005 |
2931 | GSK3A | HTA11_866_3004761011 | Human | Colorectum | AD | 2.56e-08 | 2.03e-01 | 0.096 |
2931 | GSK3A | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.99e-03 | 2.74e-01 | 0.0131 |
2931 | GSK3A | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.35e-02 | 1.90e-01 | -0.0177 |
2931 | GSK3A | HTA11_6801_2000001011 | Human | Colorectum | SER | 7.09e-04 | 3.23e-01 | 0.0171 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000042211 | Liver | HCC | autophagy of mitochondrion | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
GO:006172611 | Liver | HCC | mitochondrion disassembly | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
GO:003133022 | Liver | HCC | negative regulation of cellular catabolic process | 164/7958 | 262/18723 | 3.52e-11 | 1.35e-09 | 164 |
GO:003425022 | Liver | HCC | positive regulation of cellular amide metabolic process | 110/7958 | 162/18723 | 5.14e-11 | 1.92e-09 | 110 |
GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
GO:005134822 | Liver | HCC | negative regulation of transferase activity | 166/7958 | 268/18723 | 8.97e-11 | 3.18e-09 | 166 |
GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
GO:190374911 | Liver | HCC | positive regulation of establishment of protein localization to mitochondrion | 33/7958 | 36/18723 | 7.67e-10 | 2.37e-08 | 33 |
GO:19033221 | Liver | HCC | positive regulation of protein modification by small protein conjugation or removal | 94/7958 | 138/18723 | 9.87e-10 | 3.01e-08 | 94 |
GO:19039551 | Liver | HCC | positive regulation of protein targeting to mitochondrion | 30/7958 | 32/18723 | 1.19e-09 | 3.58e-08 | 30 |
GO:004346722 | Liver | HCC | regulation of generation of precursor metabolites and energy | 89/7958 | 130/18723 | 1.84e-09 | 5.35e-08 | 89 |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:200006022 | Liver | HCC | positive regulation of ubiquitin-dependent protein catabolic process | 76/7958 | 107/18723 | 2.06e-09 | 5.79e-08 | 76 |
GO:003243612 | Liver | HCC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 66/7958 | 90/18723 | 2.79e-09 | 7.55e-08 | 66 |
GO:001082112 | Liver | HCC | regulation of mitochondrion organization | 96/7958 | 144/18723 | 3.82e-09 | 1.02e-07 | 96 |
GO:000700612 | Liver | HCC | mitochondrial membrane organization | 80/7958 | 116/18723 | 7.09e-09 | 1.81e-07 | 80 |
GO:190353311 | Liver | HCC | regulation of protein targeting | 60/7958 | 81/18723 | 7.70e-09 | 1.94e-07 | 60 |
GO:190374711 | Liver | HCC | regulation of establishment of protein localization to mitochondrion | 41/7958 | 50/18723 | 1.14e-08 | 2.83e-07 | 41 |
GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa04728 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa047281 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
hsa049322 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa047282 | Colorectum | SER | Dopaminergic synapse | 37/1580 | 132/8465 | 5.27e-03 | 3.28e-02 | 2.38e-02 | 37 |
hsa049323 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa047283 | Colorectum | SER | Dopaminergic synapse | 37/1580 | 132/8465 | 5.27e-03 | 3.28e-02 | 2.38e-02 | 37 |
hsa049324 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa047284 | Colorectum | MSS | Dopaminergic synapse | 45/1875 | 132/8465 | 1.02e-03 | 5.94e-03 | 3.64e-03 | 45 |
hsa049325 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa047285 | Colorectum | MSS | Dopaminergic synapse | 45/1875 | 132/8465 | 1.02e-03 | 5.94e-03 | 3.64e-03 | 45 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3A | SNV | Missense_Mutation | c.430N>G | p.Leu144Val | p.L144V | P49840 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
GSK3A | SNV | Missense_Mutation | rs750207489 | c.757N>A | p.Asp253Asn | p.D253N | P49840 | protein_coding | tolerated(0.54) | benign(0.286) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
GSK3A | SNV | Missense_Mutation | c.710N>T | p.Ser237Phe | p.S237F | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
GSK3A | SNV | Missense_Mutation | c.758N>G | p.Asp253Gly | p.D253G | P49840 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1322_1323insTACAGGCGTGAAC | p.Pro442ThrfsTer26 | p.P442Tfs*26 | P49840 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
GSK3A | insertion | Frame_Shift_Ins | novel | c.1320_1321insCCGCTTGGCCTCCTAAAGTGTTGGG | p.Ile441ProfsTer31 | p.I441Pfs*31 | P49840 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
GSK3A | SNV | Missense_Mutation | novel | c.787N>A | p.Asp263Asn | p.D263N | P49840 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3A | SNV | Missense_Mutation | novel | c.616G>C | p.Ala206Pro | p.A206P | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GSK3A | SNV | Missense_Mutation | novel | c.288C>A | p.Asp96Glu | p.D96E | P49840 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
GSK3A | SNV | Missense_Mutation | c.1264N>G | p.Leu422Val | p.L422V | P49840 | protein_coding | deleterious(0) | benign(0.377) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Thiadiazolidindione derivative 2 | |||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PMID27828716-Compound-BIO-acetoxime | |||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | CHIR-99021 | CHIR-99021 | ||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | inhibitor | 249565696 | ||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PHA-767491 | CHEMBL225519 | ||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | AR-A014418 | CHEMBL259850 | ||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | KENPAULLONE | KENPAULLONE | ||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | PMID27828716-Compound-17 | |||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Maleimides derivative 3 | |||
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | Indazole derivative 6 |
Page: 1 2 3 4 5 6 7 |